Antimicrobial resistance in Pseudomonas sp. causing infections in trauma patients: A 6 year experience from a south asian country

Journal of Global Infectious Diseases

Volumn 6, Issue 4, 2014, Pages 182-185

  Rajkumari, Nonika ^a   John, Nibu Varghese ^a   Mathur, Purva ^a   Misra, Mahesh Chandra ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Antibiotic resistance; Cross resistance; Infections; Multi drug resistance; Pseudomonas spp.; Trauma

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CEFEPIME; CEFTAZIDIME; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN; TAZOBACTAM; TETRACYCLINE; TICARCILLIN; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CONTROLLED STUDY; CROSS RESISTANCE; DISK DIFFUSION; INDIA; LENGTH OF STAY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PATHOGENESIS; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS ALCALIGENES; PSEUDOMONAS FLAVESCENS; PSEUDOMONAS INFECTION; PSEUDOMONAS LUTEOLA; PSEUDOMONAS MENDOCENA; PSEUDOMONAS PUTIDA; PSEUDOMONAS STUTZERI; TRAUMATOLOGY;

EID: 84914165084     PISSN: 0974777X     EISSN: 09748245     Source Type: Journal    
DOI: 10.4103/0974-777X.145250     Document Type: Article

References (14)

1. Rossolini GM, Mantengoli E. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin Microbiol Infect 2005;11 Suppl 4:17-32
2. Giske CG, Monnet DL, Cars O, Carmeli Y, ReAct-Action on Antibiotic Resistance. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother 2008;52:813-21
3. Aris RM, Gilligan PH, Neuringer IP, Gott KK, Rea J, Yankaskas JR. The effects of panresistant bacteria in cystic fibrosis patients on lung transplant outcome. Am J Respir Crit Care Med 1997;155:1699-704
4. Park YS, Lee H, Chin BS, Han SH, Hong SG, Hong SK, et al. Acquisition of extensive drug-resistant Pseudomonas aeruginosa among hospitalized patients: Risk factors and resistance mechanisms to carbapenems. J Hosp Infect 2011;79:54-8
5. Paterson DL. The epidemiological profile of infections with multidrugresistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006;43 Suppl 2:S43-8
6. Falagas ME, Karageorgopoulos DE. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gramnegative bacilli: Need for international harmonization in terminology. Clin Infect Dis 2008;46:1121-2
7. Collee JG, Miles RS, Watt B. Tests for the identification of bacteria. In: Collee JG, Fraser AG, Marmion BP, Simmons A, editors. Mackie and McCartney Practical Medical Microbiology. 14th ed. New York: Churchill Livingstone; 1996. p. 131-45
8. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement (June 2010 update). M100-S20. Pennsylvania, USA: Clinical and Laboratory Standard Institute (CLSI) Document; 2010
9. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. M100-S22. Wayne, Pennsylvania, USA: Clinical and Laboratory Standard Institute (CLSI) Document; 2012
10. Tsutsui A, Suzuki S, Yamane K, Matsui M, Konda T, Marui E, et al. Genotypes and infection sites in an outbreak of multidrug-resistant Pseudomonas aeruginosa. J Hosp Infect 2011;78:317-22
11. Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, Bartlett JG, et al. Bad bugs need drugs: An update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006;42:657-68
12. Gülay Z, Atay T, Amyes SG. Clonal spread of imipenem-resistant Pseudomonas aeruginosa in the intensive care unit of a Turkish hospital. J Chemother 2001;13:546-54
13. Lautenbach E, Weiner MG, Nachamkin I, Bilker WB, Sheridan A, Fishman NO. Imipenem resistance among Pseudomonas aeruginosa isolates: Risk factors for infection and impact of resistance on clinical and economic outcomes. Infect Control Hosp Epidemiol 2006;27:893-900
14. Furtado GH, Bergamasco MD, Menezes FG, Marques D, Silva A, Perdiz LB, et al. Imipenem-resistant Pseudomonas aeruginosa infection at a medical-surgical intensive care unit: Risk factors and mortality. J Crit Care 2009;24:625.e9-14